Parkinson’s disease is a common neurological disorder caused by the progressive degeneration of neurons producing dopamine. Standard of care in Parkinson’s disease is treatment with dopamine replacement therapies such as Levodopa or dopamine agonists. However, in advanced stages of Parkinson’s disease, patients treated with dopamine replacement therapies often suffer from dyskinesia, a condition that strongly impacts quality of life and in severe cases can be life-threatening. By applying the basic principles fundamental to our PRECISION MEDICINE methodology, JM-010 was developed as an innovative approach to accelerate the development of new treatment options for Parkinson’s disease patients suffering from dyskinesia.
JM-010 acts as a dual molecular switch by which the target efficacies of two existing and safe medications are perfectly fine-tuned to effectively treat the disease. Using a proprietary formulation, JM-010 targets central mechanisms underlying the development of dyskinesia in Parkinson’s disease. JM-010 has successfully demonstrated its efficacy and safety in preclinical studies, as well as in Ph1 clinical safety and Ph2 clinical proof of concept studies. Currently, JM-010 is undergoing Ph2 clinical studies in Europe and US.
Contera Pharma A/S
Agern Allé 24
Thomas Sager, CEO
Jaihong Kwon, CFO
Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years.